SCHEMBL7262242

SCHEMBL7262242

C=C(C)c1ccc(C#C[Si](C)(C)C)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.31
GABRG2 P18507 1/20 0.31
GABRB3 P28472 1/20 0.31
GABRA5 P31644 1/20 0.31
GABRA3 P34903 1/20 0.31
GABRA2 P47869 1/20 0.31
SOST Q9BQB4 1/20 0.31
RARB P10826 1/20 0.31
RARG P13631 1/20 0.31
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
ALDH1A1 P00352 1/20 0.31
HPGD P15428 1/20 0.31
CYP2C19 P33261 1/20 0.31
RAB9A P51151 1/20 0.31
KMT2A Q03164 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
GRM5 P41594 1/20 0.31
FFAR1 O14842 1/20 0.30
VCP P55072 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28655847 0.81 MMP2 (0.34) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL1306384 0.80 GABRA1 (0.38) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL9636621 0.80 HPGD (0.47) RARBRARGKDM4EMEN1ALDH1A1
SCHEMBL28337840 0.79 MEN1 (0.46) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL1306505 0.78 APP (0.41) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL8049735 0.78 ALDH1A1 (0.43) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL440124 0.76 GRM5 (0.50) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL6036758 0.76 RARB (0.55) RARBRARGALDH1A1HPGDSMN1; SMN2
SCHEMBL25093690 0.74 NOS1 (0.44) RARBRARGALDH1A1CYP2C19KMT2A
SCHEMBL27027138 0.74 ESR1 (0.37) GABRA1GABRG2GABRB3GABRA5GABRA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6656957-B1 Marked and selective modulating, especially antagonistic, action at human metabotropic glutamate receptors (mGluRs); treatment of disorders such as epilepsy, cerebral ischemias, especially acute ischemias, spasticity etc. NOVARTIS AG (CH) 2003-12-02 US disclosed